Ion Channel Modulators in Cystic Fibrosis

Chest

Volumn 154, Issue 2, 2018, Pages 383-393

  Gentzsch, Martina ^a   Mall, Marcus A ^b,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BERLIN INSTITUTE OF HEALTH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cystic fibrosis; pharmacotherapy; translating basic research

Indexed keywords

AZD 5634; BI 443651; CALCIUM ACTIVATED CHLORIDE CHANNEL; CHLORIDE CHANNEL; CTC 656; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEUTIVACAFTOR; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; FDL 169; GLPG 1837; GLPG 2222; GLPG 2451; GLPG 2737; GLPG 3067; ION TRANSPORT AFFECTING AGENT; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; IVACAFTOR PLUS TEZACAFTOR; LUMACAFTOR; MRT 5005; PTI 428; PTI 801; PTI 808; QBW 251; QBW 276; QR 010; SODIUM CHANNEL; SPX 101; TEZACAFTOR; UNCLASSIFIED DRUG; VX 152; VX 440; VX 445; VX 659; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; INDOLE DERIVATIVE; ION CHANNEL; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE;

BRONCHOCONSTRICTION; CHLORIDE TRANSPORT; CTFR GENE; CYSTIC FIBROSIS; DYSPNEA; GENE FUNCTION; GENE MUTATION; GENOTYPE; HUMAN; LUNG FIBROSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT; DRUG COMBINATION; DRUG EFFECT; GENETICS;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG COMBINATIONS; GENOTYPE; HUMANS; INDOLES; ION CHANNELS; PRECISION MEDICINE; QUINOLONES;

EID: 85049346781     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2018.04.036     Document Type: Review

References (92)

1. Elborn, J.S., Cystic fibrosis. Lancet 388:10059 (2016), 2519–2531.
2. Mall, M.A., Hartl, D., CFTR: cystic fibrosis and beyond. Eur Respir J 44:4 (2014), 1042–1054.
3. Cohen-Cymberknoh, M., Shoseyov, D., Kerem, E., Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183:11 (2011), 1463–1471.
4. Stern, M., Bertrand, D.P., Bignamini, E., et al. European Cystic Fibrosis Society Standards of Care: quality management in cystic fibrosis. J Cyst Fibros 13:suppl 1 (2014), S43–S59.
5. Riordan, J.R., Rommens, J.M., Kerem, B., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:4922 (1989), 1066–1073.
6. Fajac, I., De Boeck, K., New horizons for cystic fibrosis treatment. Pharmacol Ther 170 (2017), 205–211.
7. Ramsey, B.W., Davies, J., McElvaney, N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:18 (2011), 1663–1672.
8. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:3 (2015), 220–231.
9. Van Goor, F., Straley, K.S., Cao, D., et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290:6 (2006), L1117–L1130.
10. Ma, T., Vetrivel, L., Yang, H., et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 277:40 (2002), 37235–37241.
11. Galietta, L.J., Springsteel, M.F., Eda, M., et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 276:23 (2001), 19723–19728.
12. Sosnay, P.R., Siklosi, K.R., Van Goor, F., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45:10 (2013), 1160–1167.
13. Li, W., Soave, D., Miller, M.R., et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 133:2 (2014), 151–161.
14. Corvol, H., Blackman, S.M., Boelle, P.Y., et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun, 6, 2015, 8382.
15. Welsh, M.J., Smith, A.E., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:7 (1993), 1251–1254.
16. Veit, G., Avramescu, R.G., Chiang, A.N., et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:3 (2016), 424–433.
17. Tabcharani, J.A., Chang, X.B., Riordan, J.R., et al. Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene. Nature 352:6336 (1991), 628–631.
18. Rich, D.P., Anderson, M.P., Gregory, R.J., et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347:6291 (1990), 358–363.
19. Serohijos, A.W., Hegedus, T., Aleksandrov, A.A., et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A 105:9 (2008), 3256–3261.
20. Callebaut, I., Hoffmann, B., Lehn, P., et al. Molecular modelling and molecular dynamics of CFTR. Cell Mol Life Sci 74:1 (2017), 3–22.
21. Protasevich, I., Yang, Z., Wang, C., et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci 19:10 (2010), 1917–1931.
22. Liu, F., Zhang, Z., Csanady, L., et al. Molecular structure of the human CFTR ion channel. Cell 169:1 (2017), 85–95.e88.
23. Zhang, Z., Liu, F., Chen, J., Conformational changes of CFTR upon phosphorylation and ATP binding. Cell 170:3 (2017), 483–491.e488.
24. Okiyoneda, T., Veit, G., Dekkers, J.F., et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 9:7 (2013), 444–454.
25. Mendoza, J.L., Schmidt, A., Li, Q., et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 148:1-2 (2012), 164–174.
26. Taylor-Cousar, J.L., Munck, A., McKone, E.F., et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377:21 (2017), 2013–2023.
27. Rowe, S.M., Daines, C., Ringshausen, F.C., et al. Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 377:21 (2017), 2024–2035.
28. Accurso, F.J., Rowe, S.M., Clancy, J.P., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363:21 (2010), 1991–2003.
29. Van Goor, F., Hadida, S., Grootenhuis, P.D., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106:44 (2009), 18825–18830.
30. Cystic Fibrosis Foundation Drug Development Pipeline. https://www.cff.org/Trials/Pipeline. Accessed May 12, 2018.
31. Galapagos NV Clinical Pipeline. http://www.glpg.com/clinical-pipelines. Accessed May 12, 2018.
32. McKone, E.F., Borowitz, D., Drevinek, P., et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2:11 (2014), 902–910.
33. Sawicki, G.S., McKone, E.F., Pasta, D.J., et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med 192:7 (2015), 836–842.
34. Rowe, S.M., Heltshe, S.L., Gonska, T., et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190:2 (2014), 175–184.
35. Ronan, N.J., Einarsson, G.G., Twomey, M., et al. CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor. Chest 153:2 (2018), 395–403.
36. Hisert, K.B., Heltshe, S.L., Pope, C., et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med 195:12 (2017), 1617–1628.
37. Accurso, F.J., Van Goor, F., Zha, J., et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 13:2 (2014), 139–147.
38. Rowe, S.M., Liu, B., Hill, A., et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One, 8(7), 2013, e66955.
39. Graeber, S.Y., Hug, M.J., Sommerburg, O., et al. Intestinal current measurements detect activation of mutant CFTR in patients with cystic fibrosis with the G551D mutation treated with ivacaftor. Am J Respir Crit Care Med 192:10 (2015), 1252–1255.
40. De Boeck, K., Munck, A., Walker, S., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13:6 (2014), 674–680.
41. Yu, H., Burton, B., Huang, C.J., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11:3 (2012), 237–245.
42. Davies, J.C., Cunningham, S., Harris, W.T., et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4:2 (2016), 107–115.
43. Harbeson, S.L., Morgan, A.J., Liu, J.F., et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther 362:2 (2017), 359–367.
44. Yeh, H.I., Sohma, Y., Conrath, K., et al. A common mechanism for CFTR potentiators. J Gen Physiol 149:12 (2017), 1105–1118.
45. Norman, P., Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and WO2013038390. Expert Opin Ther Pat 24:7 (2014), 829–837.
46. Clancy, J.P., Rowe, S.M., Accurso, F.J., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67:1 (2012), 12–18.
47. Boyle, M.P., Bell, S.C., Konstan, M.W., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:7 (2014), 527–538.
48. Rowe, S.M., McColley, S.A., Rietschel, E., et al. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann Am Thorac Soc 14:2 (2017), 213–219.
49. Cholon, D.M., Quinney, N.L., Fulcher, M.L., et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med, 6(246), 2014 246ra296.
50. Veit, G., Avramescu, R.G., Perdomo, D., et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med, 6(246), 2014 246ra297.
51. Graeber, S.Y., Dopfer, C., Naehrlich, L., et al. Effects of lumacaftor/ivacaftor therapy on CFTR function in Phe508del homozygous patients with cystic fibrosis. Am J Respir Crit Care Med 197:11 (2018), 1433–1442.
52. Hirtz, S., Gonska, T., Seydewitz, H.H., et al. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 127:4 (2004), 1085–1095.
53. Ratjen, F., Hug, C., Marigowda, G., et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med 5:7 (2017), 557–567.
54. Talamo Guevara, M., McColley, S.A., The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf 16:11 (2017), 1305–1311.
55. Grasemann, H., CFTR modulator therapy for cystic fibrosis. N Engl J Med 377:21 (2017), 2085–2088.
56. Molinski, S.V., Ahmadi, S., Ip, W., et al. Orkambi(R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med 9:9 (2017), 1224–1243.
57. Rabeh, W.M., Bossard, F., Xu, H., et al. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 148:1-2 (2012), 150–163.
58. Meng, X., Clews, J., Kargas, V., et al. The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability. Cell Mol Life Sci 74:1 (2017), 23–38.
59. Vertex Press Release: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1055958. February 1, 2018.
60. Strug, L.J., Gonska, T., He, G., et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet 25:20 (2016), 4590–4600.
61. Cholon, D.M., Gentzsch, M., Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros 17:suppl 2 (2018), S52–S60.
62. Dekkers, J.F., Wiegerinck, C.L., de Jonge, H.R., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 19:7 (2013), 939–945.
63. Dekkers, J.F., Berkers, G., Kruisselbrink, E., et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med, 8(344), 2016 344ra384.
64. Brewington, J.J., Filbrandt, E.T., LaRosa, F.J. III, et al. Detection of CFTR function and modulation in primary human nasal cell spheroids. J Cyst Fibros 17:1 (2018), 26–33.
65. Guimbellot, J.S., Leach, J.M., Chaudhry, I.G., et al. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight, 2(22), 2017.
66. Gentzsch, M., Boyles, S.E., Cheluvaraju, C., et al. Pharmacological rescue of conditionally reprogrammed cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 56:5 (2017), 568–574.
67. Crane, A.M., Kramer, P., Bui, J.H., et al. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Reports 4:4 (2015), 569–577.
68. Mall, M.A., Galietta, L.J., Targeting ion channels in cystic fibrosis. J Cyst Fibros 14:5 (2015), 561–570.
69. Li, H., Salomon, J.J., Sheppard, D.N., et al. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Curr Opin Pharmacol 34 (2017), 91–97.
70. Mall, M., Bleich, M., Greger, R., et al. The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 102:1 (1998), 15–21.
71. Mall, M., Grubb, B.R., Harkema, J.R., et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10:5 (2004), 487–493.
72. Pons, G., Marchand, M.C., d'Athis, P., et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 30:1 (2000), 25–31.
73. Lennox, A., Myerburg, M.M., SPX-101 is a promising and novel nebulized ENaC inhibitor. Am J Respir Crit Care Med 196:6 (2017), 671–672.
74. Reihill, J.A., Walker, B., Hamilton, R.A., et al. Inhibition of protease-epithelial sodium channel signaling improves mucociliary function in cystic fibrosis airways. Am J Respir Crit Care Med 194:6 (2016), 701–710.
75. Crosby, J.R., Zhao, C., Jiang, C., et al. Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. J Cyst Fibros 16:6 (2017), 671–680.
76. Moss, R.B., Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162:4 (2013), 676–680.
77. Ratjen, F., Durham, T., Navratil, T., et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 11:6 (2012), 539–549.
78. Caputo, A., Caci, E., Ferrera, L., et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322:5901 (2008), 590–594.
79. Namkung, W., Yao, Z., Finkbeiner, W.E., et al. Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J 25:11 (2011), 4048–4062.
80. Lim, N.K., Lam, A.K., Dutzler, R., Independent activation of ion conduction pores in the double-barreled calcium-activated chloride channel TMEM16A. J Gen Physiol 148:5 (2016), 375–392.
81. Liu, X., Li, T., Riederer, B., et al. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice. Pflugers Arch 467:6 (2015), 1261–1275.
82. Bertrand, C.A., Zhang, R., Pilewski, J.M., et al. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol 133:4 (2009), 421–438.
83. Anagnostopoulou, P., Riederer, B., Duerr, J., et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 122:10 (2012), 3629–3634.
84. Sun, L., Rommens, J.M., Corvol, H., et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44:5 (2012), 562–569.
85. Mutyam, V., Du, M., Xue, X., et al. Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations. Am J Respir Crit Care Med 194:9 (2016), 1092–1103.
86. Alton, E.W., Beekman, J.M., Boyd, A.C., et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax 72:2 (2017), 137–147.
87. Dhooghe, B., Haaf, J.B., Noel, S., et al. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis. Expert Opin Investig Drugs 25:4 (2016), 423–436.
88. Clunes, L.A., Davies, C.M., Coakley, R.D., et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 26:2 (2012), 533–545.
89. Dransfield, M.T., Wilhelm, A.M., Flanagan, B., et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 144:2 (2013), 498–506.
90. Solomon, G.M., Fu, L., Rowe, S.M., et al. The therapeutic potential of CFTR modulators for COPD and other airway diseases. Curr Opin Pharmacol 34 (2017), 132–139.
91. Anderson, W.H., Coakley, R.D., Button, B., et al. The relationship of mucus concentration (hydration) to mucus osmotic pressure and transport in chronic bronchitis. Am J Respir Crit Care Med 192:2 (2015), 182–190.
92. Kesimer, M., Ford, A.A., Ceppe, A., et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med 377:10 (2017), 911–922.